ANXA1 and central nervous system cancer: Consistently, the immunohistochemistry (IHC) experiments of glioma patients (WHO II–IV grade) showed that ANXA1 was the highest in WHO IV patients and lowest in WHO II patients (all p < 0.05, Figures 1M–N).